Eyenuk

Eyenuk offers AI triage solutions to identify and prioritize patients who require urgent specialist eye care.

Eyenuk's AI eye screening solution, EyeArt, provides rapid, accurate, and autonomous disease detection without the need for an eye specialist.

The page presents clinical evidence on Eyenuk's EyeArt AI system, including peer-reviewed evidence of diagnostic accuracy and autonomous eye screening safety.

Expert insights on autonomous AI retinal screening, diabetic retinopathy detection, health equity, and FDA-cleared diagnostic systems for primary care.

The page describes a clinical study comparing Eyenuk's EyeArt AI system with ophthalmologists' dilated exams for detecting more than mild diabetic retinopathy.

Analyze the diagnostic accuracy and cost-effectiveness of Eyenuk's automated diabetic retinopathy image assessment software compared against human graders.

Eyenuk AI technology has been selected for diabetic eye testing in Vietnam, supported globally by the renowned Fred Hollows Foundation.

Eyenuk appoints Mads Dall as Chairman of the Board and Gaurav Agarwal as Chief Executive Officer to lead the AI digital health company.

Eyenuk has officially been granted CE Marking for EyeArt, allowing the autonomous AI eye screening system to be utilized across Europe.

Eyenuk joins the Population Health Alliance, paving the way for autonomous AI to actively improve diabetic complications and patient care.

EyeArt by Eyenuk is an autonomous, FDA-cleared AI for diabetic retinopathy screening and disease detection at the point of care.

Eyenuk's Privacy Policy explains how the company protects personal information and addresses GDPR, HIPAA, and cybersecurity compliance for its AI solutions.